LINC00641 is downregulated in bladder cancer, cervical cancer, breast cancer, prostate cancer, non-small cell lung cancer, glioma and cutaneous squamous cell carcinoma, and can be used as a tumor suppressor gene, while it is up-regulated in acute myeloid leukemia, gastric cancer, rectal cancer and renal cell carcinoma, and can be used as oncogene. Here, LINC00641 is linked to prostate carcinoma.